GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Who Owns My Stored Stem Cells?

Short answer: paying for private stem-cell storage does not, by itself, give the bank permission to use your cells however it chooses. But being the cell source does not establish unlimited legal ownership either. Your consent, storage agreement, and applicable law determine who can authorize use, transfer, or destruction. Public donation is different: do not assume the cells remain reserved for you.

Start with your informed consent and storage contract, read together with the law that applies to the arrangement. Safety and tracking rules answer a different question from ownership. In the United States, 21 CFR 1271.290 requires establishments handling HCT/Ps within its scope to track them from donor to consignee and back using a distinct identification code, to support investigation and correction of communicable-disease transmission Section 1271.290. That is a traceability requirement, not proof that a particular bank complies, that a treatment works, or that the donor has unlimited control.

Who Owns My Stored Stem Cells?

What Ownership Usually Means

Forget the legal jargon for a minute. Most people want answers to five questions:

  • Are the cells still mine after collection and freezing?
  • Can the clinic use, sell, share, or study them without asking me again?
  • Can I get them moved to another facility, or ask for them to be destroyed?
  • What happens if I stop paying, if the bank closes, or if I die?
  • If the cells were collected from my child or donated by someone else, who decides?

Separate three questions: whose body the cells came from, who physically holds them, and who has authority to make decisions. Those may involve different people. This article explains what to check in your documents; it does not determine legal title to a particular sample.

Your Own Stored Cells

A typical private-storage case is autologous storage. That means fat, blood, dental pulp, or another tissue is taken from you, processed, frozen, and kept for your own possible future use.

Check that the agreement identifies the material, the person it is reserved for, the permitted purpose, and the storage period and fee. A promise to store cells is not the same as permission to donate, research, or commercially develop them. Ask the bank to identify every clause granting those permissions rather than relying on the word “ownership” in a brochure.

Ask for written procedures for release, transfer, and destruction, including identity checks and costs. These contractual terms do not replace rights or restrictions imposed by law. Storage is no promise that the cells will survive thawing in usable amounts, suit you medically later, or have an available, approved treatment that works for you.

US tissue regulation answers a different question. FDA describes human cells, tissues, and cellular and tissue-based products, or HCT/Ps, and rules intended to reduce communicable-disease transmission Tissue tissue products. Requirements depend on the product and intended use. For example, FDA’s cord-blood guidance distinguishes personal or family use from unrelated-recipient use and notes an infectious-disease donor-screening and testing exception when the cells are used for the original donor Cord blood banking information consumers. Do not interpret a bank’s registration, testing, or inspection status as a ruling on ownership.

Purpose Clause

Check whether the purpose clause limits use to the same clinic group, permits transfer to another medical facility, or allows extra processing at added cost. These are different arrangements, not interchangeable promises. If transfer or outside use is unclear, ask for written clarification before signing. Read this clause alongside the consent and release terms, not as the sole answer to who controls the cells.

Cord Blood and Family Banking

Cord blood and cord tissue involve three roles: the newborn child as the source, a parent who signs and pays, and the bank as custodian.

Do not assume the person paying the fees has sole authority over a child’s cells. Ask the bank to name the account holder and explain who can consent to release, whether one parent or both must agree, what changes when the child becomes an adult, and whether sibling or relative use is permitted. If parents disagree or separate, obtain advice under the applicable law rather than treating the account name as decisive.

If a salesperson’s promise differs from the paperwork, resolve the mismatch in writing before signing.

FDA describes public cord-blood banking as storage for potential use by anyone who may need it, unlike private banking for potential use by the child or certain relatives Cord blood banking information consumers. Public donation therefore is not a reservation for your family. Ask the program whether withdrawal is possible, at what stage, and what happens after a unit has been allocated or used.

FDA’s approved cellular and gene therapy products list includes named cord-blood products such as HEMACORD and ALLOCORD Approved cellular and gene therapy products. This is not an ownership register or a list of all lawfully stored family units. FDA explains that personal or certain related-family cord-blood uses meeting its regulatory criteria do not require pre-use approval; unrelated-recipient use requires a biologics license or an investigational new drug application Cord blood banking information consumers. Neither paying for storage nor identifying a regulatory route establishes that a proposed treatment is suitable for you.

Donated Cells

For tissue donation beyond public cord-blood banking, read the actual program consent. Check the authorized purpose, permitted recipients, storage and disposal terms, and any withdrawal limits. A donation for another person’s treatment is not automatically consent for every research or commercial use.

Before applying someone else’s story to yourself, check whether it concerns a donation under program consent or private storage under a storage agreement.

For example, a donor asking whether a unit remains available needs the donation program’s allocation and withdrawal rules. A storage customer asking to move a sample needs the bank’s release terms and a receiving facility’s acceptance. These are different requests even when both people call the cells “mine.”

For private storage, ask whether the documents authorize research, commercial development, genetic testing, or sharing of samples or data. Identify which permissions are optional and whether refusing them affects the storage service. Do not assume that separate paperwork is always required or that removing your name from a sample answers every consent question. Ask what permission or other legal basis the bank relies on for each use.

Who Controls Each Storage Type

Situation Who holds decision power Can the holder pass your cells to someone else Can you order transfer or destruction
Your own privately stored cells The person authorized under the agreement and applicable law Check the permitted-use and disclosure clauses; storage alone is not permission Check release rights, restrictions, fees, and the receiving facility’s requirements
Private family cord-blood unit Authorized parent, guardian, or later the adult child, as applicable Only as the agreement and medical consent allow Depends on the agreement and the receiving facility
Publicly donated cord blood The bank system, under its rules Yes, to a matching patient by design Not reserved for the donor; check withdrawal terms and allocation status
Licensed cell product Not a personal storage account; prescribing and supply follow the product’s authorized pathway Under medical and regulatory controls Destruction and return follow medical rules, not a storage contract

This table is a document-checking guide, not a statement of property law. A contract cannot by itself override applicable legal protections or restrictions.

Permissions to Confirm With the Bank

For material intended to remain reserved for you, ask the provider to confirm these safeguards and identify any exceptions:

  • No release to another patient unless the relevant consent and legal requirements are met.
  • No sale or sharing outside the permissions and legal basis identified in the documents; samples and identifying information should be addressed separately.
  • A clear explanation of whether research or product development is authorized, and how to decline optional uses.
  • It should label what it holds so each item stays linked to you, with a distinct code rather than a vague note, and be able to explain its labeling and tracking procedures, consistent with the tracking duties described above Section 1271.290, and its own written release and destruction procedures.
  • On request, it should give you a straight account of what is stored for you: where, for how long, at what cost, and how to ask for transfer or destruction.

Your consent cannot force a clinic to provide an unsafe, unlawful, or medically unsuitable treatment. Before authorizing research, ask how to withdraw, whether identifiable samples or data can still be located, and what happens to material already used or shared. Do not assume withdrawal can reverse completed work.

Moving or Destroying Cells

Before requesting transfer, obtain written acceptance from the receiving facility and ask both facilities to confirm release checks, shipment conditions, costs, and any cross-border permissions. Permission to move a sample is different from a clinician agreeing to use it.

For destruction, ask who must sign, what material will be destroyed, how the action is confirmed, and what records must remain afterward. Sample destruction and deletion of medical or traceability records are separate questions; do not assume one automatically triggers the other. Keep the request and confirmation.

Transfer Checklist

  • What exactly is stored under my name, including the number of vials or batches, labels, and dates?
  • Is the material reserved only for me, and for what stated purpose?
  • What release or quality checks are required before any future use, and who pays for them?
  • What are the packing, temperature, timing, identity-check, and receipt requirements for shipment?
  • Who is responsible if the shipment is delayed, arrives outside the required conditions, or is refused?

Ten vials don’t automatically mean ten future treatments. How far one batch goes depends on cell quantity, processing, recovery after thawing, further preparation, and the dose a future protocol would require.

Payments, Closure and Death

Missed Payments and Your Rights

Check whether nonpayment terms allow late fees, suspension of release, or eventual disposal, and whether those terms are enforceable where the cells are stored. Ask about any grace period, how notices are sent, and who is contacted if you cannot be reached. Do not assume a universal grace period or that a missed payment transfers ownership to the bank.

If the Bank Closes or Moves Your Cells

If the business closes, merges, or moves the work elsewhere, the provider should spell out what happens to your material — how you’ll be told, whether your contract passes to a named successor, and what choices you get. Get the legal name and address of whoever physically holds the cells, not just the brand on the website.

Death, Incapacity, and Who Decides Next

Ask how to appoint a representative for incapacity and record instructions for death. An emergency contact, account payer, legal representative, and heir are not interchangeable roles. Have a local lawyer check who would have authority and whether your instructions can be carried out. For a child’s cells, also ask how decision-making changes at adulthood.

Rules in Japan and the United States

Ownership answers differ by country — and sometimes by state. The United States and Japan examples below only illustrate that split; they are not a survey of the law everywhere.

In Japan, distinguish product approval from a provider’s regulatory paperwork. PMDA’s approved-products page, checked on November 9, 2026, labels its regenerative medical products list “April 2015 to July 2026” 0002. PMDA also describes two frameworks that took effect in November 2014: the Act on the Safety of Regenerative Medicine for cell-therapy research and medical practice, and the PMD Act for commercialization of regenerative medical products 0003. A clinic filing or facility notification is not the same as product approval. Neither a filing nor a product list establishes your contractual rights to a stored sample or guarantees a benefit from treatment.

In the United States, do not read a tissue regulation as a property-title decision. For example, the federal definition of autologous use describes cells or tissue returned to the individual from whom they were recovered Section 1271.3. It defines the donor-recipient relationship, not who can resolve a dispute between parents, authorize release after death, or demand a transfer. Take those questions, with the actual documents, to a lawyer in the relevant jurisdiction.

If your cells would be collected in one country and stored or used in another, ask which country’s rules apply at each step. Get the answer in writing before collection.

Before You Store

Review the full consent form, storage agreement, fee schedule, privacy notice, and any research or genetic-testing consent side by side. Mark the clauses naming permitted users, transfer and destruction conditions, and substitute decision makers. If an answer is missing or conflicts across documents, ask the provider to resolve it before you sign or pay.

A hypothetical document check: suppose a brochure says “your cells remain yours,” but the agreement permits release only to the bank’s associated clinic. Before assuming you can move them elsewhere, ask the provider to identify the transfer clause, confirm whether an outside facility can receive them, and itemize release and shipping charges. This is an illustration, not a reported patient case.

  • The exact purpose and permitted users of the stored material
  • The storage period, renewal date, fees, and what happens after a missed payment
  • Transfer, release, and destruction procedures and costs
  • Closure, relocation, and successor arrangements
  • Named decision makers for children, joint accounts, incapacity, and death
  • Privacy, data sharing, and any optional research or commercial uses
  • Complaint contacts and how disputes are resolved

Keep your signed copies, payment receipts, sample labels or batch numbers, and every later notice together in one place. Tell someone you trust where they are. If anything important was promised out loud, get it written into the agreement or confirmed in an email from the provider.

Stored cells are not a treatment guarantee. Freezing preserves material under defined conditions, but later use still requires medical assessment, quality and safety checks, an available lawful treatment pathway, and your fresh consent at the time.

No bank can promise your cells will be enough, suitable, or effective for some future illness.

Before you commit: obtain a written answer to who can authorize use, who can request transfer or destruction, and who acts if you cannot decide. If the documents are unclear, ask an independent lawyer in the relevant jurisdiction to review them. A qualified clinician should assess any proposed treatment separately from the storage purchase. This article is general information, not individual legal or medical advice.

Considering cell storage connected with treatment in Japan?

Use the contact form to ask about preparing for a physician consultation. Ask how to submit documents securely before sending sensitive medical information. Contract disputes need independent legal advice.

Contact the Support Team